I had a conversation with Brian Kelly, life sciences and diagnostics professional. Brian's career is expansive but working with pharma on advanced diagnostics has been his passion for the last dozen years. Precision therapy is not a simple triangle. A lot of parties are involved. Molecular classification of disease has evolved. MSI, BRAF, KRAS has crossed the silicon valley chasm from early adoptors to main street. The FDA and the other global approval bodies deserve a lot of credit for upping their game in the approval process, especially over the last decade. There's still a lot to be done to educate and inform, and Brian is someone who has seen it firsthand with his wife who had early colorectal cancer, who does not have Lynch but is MSI High, and thankfully is doing well. The ecosystem still matters, and we need to continue to strive for better.
